AXL receptor, a transmembrane kinase receptor and member of TYRO3, AXL and MERTK (TAM) family, was first characterized in chronic myeloid leukemia in 1991 and thereafter has been identified in a variety of malignancies such as breast, esophageal, and non‐small cell lung cancers (NSCLC), as well as in RCC (Chung et al., 2003; Gay et al., 2017). This evidence concerns the gene AXL and renal cell adenocarcinoma.